Degenerative Disc Disease Therapeutic Pipeline Analysis of 12 Companies and 17 Drugs H1 2015 Review Research Report

DALLAS, March 9, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Degenerative Disc Disease - Pipeline Review, H1 2015" therapeutic market research report of 72 pages with latest updates, data and information to its online business intelligence library.

The report Degenerative Disc Disease Pipeline Review, H1 2015 provides an overview of the Degenerative Disc Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects.for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects. Complete report is available @ http://www.rnrmarketresearch.com/degenerative-disc-disease-pipeline-review-h1-2015-market-report.html .

Degenerative disc disease is one of the most common causes of low back pain and neck pain, and also one of the most misunderstood. Degenerative disc disease is typically associated with aging. Disc degeneration can occur at the cervical, thoracic and lumbar levels of the spine, possibly causing pain in the affected area and radiating pain along the nerves emerging from the spinal canal. Degenerative disc disease may cause back and/or leg pain, as well as functional problems such as tingling or numbness in your legs or buttocks, or difficulty walking.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this report include: AnGes MG, Inc., Biogenomics Limited, Bioheart, Inc., BioRestorative Therapies, Inc., Bone Therapeutics SA, DePuy Spine, Inc., Discgenics, Inc, ISTO Technologies, Inc., K-Stemcell Co., Ltd., Mesoblast Limited, TissueGene, Inc., Yuhan Corporation. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=308857 . (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include: AdipoCell, ALLOB, brtxDISC, CHND-1, dibotermin alfa, MPC-25Osteo, NuQu Cell-Based Therapy, Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders, Poly N-Acetyl Glucosamine Hydrogel, Recombinant Protein for Degenerative Disc Disease, S-414114, Stem Cell Therapy, Stem Cell Therapy for Degenerative Disc Disease, Stem Cell Therapy for Degenerative Disc Disease, Stem Cell Therapy for Degenerative Disc Disease, TG-D, YH-14618.

Featured News & Press Releases cover by this report includes: Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA; Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA; Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease; Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion; Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease; Mar 07, 2014: Stem Cell Transplant Shows "Landmark" Promise for Treatment of Degenerative Disc Disease.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports of Central Nervous System (CNS) therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics .

Other Related Reports:

Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2015

The report Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2015 provides an overview of the Spinal Muscular Atrophy (SMA)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Spinal Muscular Atrophy (SMA). Companies discussed in this report include Bioblast Pharma Ltd., Cellular Biomedicine Group, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Genethon , Genzyme Corporation, GMP-Orphan SAS, Isis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Nexgenix Pharmaceuticals, LLC, Novartis AG, OrphageniX, Inc., Paratek Pharmaceuticals, Inc., Pfizer Inc., PTC Therapeutics, Inc., Retrophin Inc., Sarepta Therapeutics, Inc., Trophos SA, Vybion, Inc., Zambon Company S.p.A.

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Companies discussed in this report include Acorda Therapeutics, Inc., aTyr Pharma, Inc., GeNeuro SA, INSYS Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation, Neuren Pharmaceuticals Limited, Pfizer Inc., RegeneRx Biopharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com

Connect with Us:
G+ / Google Plus: https://plus.google.com/u/0/104156468549256253075/
Twitter: https://twitter.com/RnRMR
Facebook: http://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed